Lilly Funding Study Of Corcept's Corlux For Mitigation Of Zyprexa Weight Gain
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies will share data from the proof-of-concept study, but they do not intend to commercially pursue the use of both drugs in combination.
You may also be interested in...
Corcept’s Second Corlux Phase III Trial Enrolled For Psychotic Major Depression
Company expects data from three Phase III trials of mifepristone for PMD by year-end.
Corcept’s Second Corlux Phase III Trial Enrolled For Psychotic Major Depression
Company expects data from three Phase III trials of mifepristone for PMD by year-end.
Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects
CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.